The global market for oncology diagnostics is estimated to increase from $77.6 billion in 2024 to reach $101.5 billion by 2029, at a compound annual growth rate (CAGR) of 5.5% from 2024 through 2029.
The oncology diagnostics market is growing at a steady rate driven by the increasing incidence and the prevalence of a wide range of cancers globally, R&D and new product launches by the major players in the market, strategic initiatives by the major players, and increasing numbers of private diagnostic centers in emerging markets.
The market is divided into the following segments: diagnostic imaging, tumor biomarker tests, endoscopy, biopsy, hematoxylin and eosin (H&E) staining, immunohistochemistry (IHC), in situ hybridization (ISH), polymerase chain reaction (PCR), next generation sequencing (NGS) and others (cytology, microarrays, exosomes, flow cytometry, sanger sequencing, pyrosequencing etc.). The market is segmented by application into breast cancer, lung cancer, colorectal cancer, prostate cancer, gastric cancer and other cancers (lip, oral/cavity, liver/gallbladder, pancreas, melanoma, kidney, bladder, brain, central nervous system, thyroid, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma and leukemia). By end user, the market is segmented into hospitals/cancer centers/clinics, diagnostic imaging centers/reference laboratories, and other end users (physician offices, research, academic institutes, national cancer registries and contract research organizations).
Regional market analysis is provided for North America, Europe, Asia-Pacific, South America and Middle East and Africa. The report also provides country-level analyses of markets and market segments. North America comprises the U.S., Canada and Mexico, while South America includes Brazil, Argentina and the rest of South America. In Europe, major countries covered are Germany, France, the U.K., Italy and Spain, along with the rest of Europe, which includes Switzerland, Denmark, Norway, Poland, Belgium, Austria, the Netherlands, Sweden, Russia and others. The Asia-Pacific region consists of Japan, China and India, as well as the rest of Asia-Pacific (Australia, New Zealand, Taiwan, Singapore, Malaysia, Thailand, the Philippines, South Korea, Indonesia etc.), and the Middle East and Africa.
The base year for the study is 2023, 2024 is the estimated year, with projections through 2029, including compound annual growth rates (CAGRs) for the forecast period.
The oncology diagnostics market is growing at a steady rate driven by the increasing incidence and the prevalence of a wide range of cancers globally, R&D and new product launches by the major players in the market, strategic initiatives by the major players, and increasing numbers of private diagnostic centers in emerging markets.
Report Scope
This report analyzes the oncology diagnostics market and the competitive landscape. The profiles of several leading companies, including their revenues, product portfolios and recent activities are also examined. The report analyzes market dynamics, including drivers, limitations, challenges and opportunities, and discusses current and potential market size. The report will enable companies in the industry to make informed decisions about the production and licensing of goods and services.The market is divided into the following segments: diagnostic imaging, tumor biomarker tests, endoscopy, biopsy, hematoxylin and eosin (H&E) staining, immunohistochemistry (IHC), in situ hybridization (ISH), polymerase chain reaction (PCR), next generation sequencing (NGS) and others (cytology, microarrays, exosomes, flow cytometry, sanger sequencing, pyrosequencing etc.). The market is segmented by application into breast cancer, lung cancer, colorectal cancer, prostate cancer, gastric cancer and other cancers (lip, oral/cavity, liver/gallbladder, pancreas, melanoma, kidney, bladder, brain, central nervous system, thyroid, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma and leukemia). By end user, the market is segmented into hospitals/cancer centers/clinics, diagnostic imaging centers/reference laboratories, and other end users (physician offices, research, academic institutes, national cancer registries and contract research organizations).
Regional market analysis is provided for North America, Europe, Asia-Pacific, South America and Middle East and Africa. The report also provides country-level analyses of markets and market segments. North America comprises the U.S., Canada and Mexico, while South America includes Brazil, Argentina and the rest of South America. In Europe, major countries covered are Germany, France, the U.K., Italy and Spain, along with the rest of Europe, which includes Switzerland, Denmark, Norway, Poland, Belgium, Austria, the Netherlands, Sweden, Russia and others. The Asia-Pacific region consists of Japan, China and India, as well as the rest of Asia-Pacific (Australia, New Zealand, Taiwan, Singapore, Malaysia, Thailand, the Philippines, South Korea, Indonesia etc.), and the Middle East and Africa.
The base year for the study is 2023, 2024 is the estimated year, with projections through 2029, including compound annual growth rates (CAGRs) for the forecast period.
The report includes:
- 94 data tables and 59 additional tables
- Analyses of global market trends for oncology diagnostics, with market revenue data from 2021 to 2024, forecasts and projected CAGRs through 2029
- Estimates of the size and growth of the global market, and a corresponding market share analysis by product type, application, end user, and region
- Facts and figures pertaining to the major market dynamics, opportunities and challenges, emerging technologies, regulations, and impacts of macroeconomic variables
- Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses
- Coverage of treatments in development for late- and early-stage oncolytic viruses, along with epidemiological information, data corresponding to cancer incidence and mortality trends
- Evaluation of recent patent activity featuring key granted and published patents
- Insights into oncology therapeutics research activity, emerging technologies, clinical trials and pipeline products
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Danaher Corp., Agilent Technologies Inc., Siemens Healthineers AG, and GE HealthCare
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologies and Developments
Chapter 6 Oncology Diagnostics Market
Chapter 7 Competitive Intelligence
Chapter 8 Sustainability in the Market for Oncology Diagnostics: An ESG Perspective
Chapter 9 Appendix
List of Tables
List of Figures
Companies Mentioned
- Abbott
- Agilent Technologies Inc.
- BD
- bioMérieux
- Bio-Rad Laboratories Inc.
- Danaher Corp.
- F. Hoffmann-La Roche Ltd.
- GE Healthcare
- Illumina Inc.
- Koninklijke Philips N.V.
- Merck KGaA
- Myriad Genetics Inc.
- QIAGEN
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc.
- ZytoVision GmbH
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 192 |
| Published | May 2025 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value ( USD | $ 77.6 Billion |
| Forecasted Market Value ( USD | $ 101.5 Billion |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
